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Objective: Schizophrenia and other psychoses have devastating 
personal and social impacts and many efforts have been devoted to 
study ‎prodromal syndromes for psychosis in order to achieve earlier 
detection and interventions. However, only few studies have 
been ‎performed in developing countries on this subject, and there is a 
dearth of evidence in the Iranian population. In this study, we ‎focused on 
conversion rate to psychosis and changes in prodromal symptoms in a 
group of first-degree relatives of patients with ‎schizophrenia and to 
compare the conversion rate in those with and without prodromal 
symptoms as assessed by the Structured ‎Interview for Prodromal 
Syndromes (SIPS) and Scale of Prodromal Symptoms (SOPS).‎ 
Method: Participants were the first-degree relatives of hospitalized 
patients with schizophrenia at Roozbeh Hospital, Tehran, Iran. At 
baseline, ‎a trained psychiatrist interviewed the participants using the SIPS 
and the SOPS and assigned them to high- or low-risk groups either ‎based 
on the presence of prodromal criteria or seeking mental health services. 
After 12 months, the same examiner re-evaluated ‎the participants in order 
to determine the changes in their symptoms and identify the probable 
transitions to psychosis.‎ 
Results: One hundred participants, 50 participants within each of high- or 
low-risk groups, were recruited at baseline. Eight participants ‎dropped out 
of the study. At the follow-up, the rate of transition to full psychosis among 
high-risk group was 13% (95% CI [0.029, ‎0.23]), whereas none of the low-
risk participants developed psychosis. None of the high-risk participants 
demonstrated attenuation ‎in their prodromal states after a one-year 
follow-up. In contrast, of the 50 low-risk participants, three experienced 
prodromal ‎symptoms for psychosis during this period. High-risk 
participant’s‎ illustrated‎ higher‎ severity‎ in almost all of the SOPS items 
compared ‎to the low-risk participants at both baseline and follow-up 
evaluations.‎ 
Conclusion: Prodromal syndrome for psychosis based on the SIPS and 
the SOPS was a predictive factor for transition to psychosis after a 12-
‎month period in a group of first-degree relatives of patients with 
schizophrenia admitted to a psychiatric hospital in Iran. 
Conducting ‎further studies on this at-risk population is highly 
recommended in order to provide practical methods for early screening 
and ‎therapeutic interventions.‎ 
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Schizophrenia and other psychoses are among the 
leading mental illnesses contributing to the global 
burden of diseases (1). ‎Schizophrenia affects 
approximately about seven to eight individuals per 
1,000 during their lifetime worldwide (2), and 
imposes ‎considerable economic burden globally, 
including direct healthcare costs and indirect costs 
associated with loss of productivity (3–
8). ‎Schizophrenia and other psychoses have debilitating 
impacts‎on‎the‎patients’‎well-being and dramatically  
 
 
 
 
impair their functioning in ‎all aspects of their lives. In 
addition to economic burden, it also has considerable 
impact on relatives, caregivers and others who are ‎in 
contact with patients (9–12). In response to such 
devastating personal and social costs of schizophrenia, 
early identification in the ‎hopes of preventing 
psychosis‎ or‎ at‎ least‎ delaying‎ it‎ at‎ “pre-psychosis”‎ or‎
prodromal period seems to be a rational choice. 
Although symptoms of pre-psychosis have been 
recognized since 1959 by Meares (9), early 
identification and intervention programs in the ‎pre-
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psychosis period dates back to the early 1990s. Among 
those initiating this movement are McGorry, Yung and 
colleagues in ‎Australia in 1994, and Miller and 
colleagues at Yale University, which then spread 
worldwide. The pre-psychosis period is the 
time ‎interval between the first noticeable changes in 
the behavior to the appearance of overt psychotic 
symptoms of schizophrenia and is ‎variably called 
“clinical‎high‎risk”‎(CHR),‎“ultra-high‎risk“(UHR),‎or‎
“(putatively)‎prodromal”‎(13–15). ‎ 
The prodromal state period that on average can last 
days up to years for five years (16, 17) is a golden time 
to initiate treatment ‎towards better prognosis based on 
two major arguments (18). First is the reduction of the 
duration of untreated psychosis (DUP) as it ‎is shown 
that prolonged DUP has a devastating role in biological 
functioning of the brain (19). In addition, it is 
hypothesized that poor ‎prognosis of earlier illness onset 
may be related to a prolonged DUP rather than solely 
the younger age of onset. Schimmelmann ‎and 
colleagues have shown that reducing the duration of 
untreated psychosis equipoised the effect of earlier 
illness onset as a poor ‎prognosis factor (20). Second is 
the prevention of the pronounced functional decline as 
one of the major predictors of the transition ‎from 
prodromal state to full psychosis. It is also shown in 
retrospective studies that patients dated the onset of 
their functional ‎decline back to the prodromal, pre-
psychotic phase (17). Therefore, early detection and 
initial treatment strategy of prodromal ‎phase of 
psychosis should become a major goal of psychiatric 
services in order to delay the onset of full psychosis 
(21), reducing ‎unnecessary suffering and increasing the 
possibility of improved long-term outcome (22, 23).‎ 
Two sets of instruments are widely employed to 
diagnose prodromal syndromes and measure the 
severity of associated symptoms. ‎First is the 
Comprehensive Assessment of At-Risk Mental States 
(CAARMS) developed by the Personal Assessment 
and Crisis ‎Evaluation Clinic in Melbourne, Australia, 
and the other is the Structured Interview for Prodromal 
Syndromes (SIPS) developed by the ‎Prevention 
through Risk Identification, Management, and 
Education (PRIME) prodromal research team at Yale 
University. The ‎severity of symptoms of SIPS criteria 
are measured by a comprehensive tool called the Scale 
of Prodromal Symptoms (SOPS) ‎developed by Miller 
et al. and McGlashan et al. (24, 25).‎ 
Previous investigations have reported the transition 
rates to psychosis ranged from 6.6% (26) to 54% (27) 
with a mean follow-up ‎range of 6 to 12 months (9). 
Only one study with the 9.6-year follow-up reported 
70% conversion rate in patients identified by 
basic ‎symptoms (28). The highest likelihood of 
conversion was found to occur within the first year 
after recognition of the psychosis risk ‎syndrome with 
no or significantly smaller further conversion rates 
thereafter (9). It is confirmed by some studies that 
reported the ‎transition rate point by point during the 
follow-up (18, 29 and 30). ‎ 
First-degree relatives are among the best candidates for 
the detection of the prodromal syndromes and the 
implementation of any ‎early intervention and 
prevention efforts. To our knowledge, to date, no study 
has focused on the prognostic value of 
prodromal ‎syndromes specifically based on SIPS and 
SOPS in this at-risk population. Therefore, we aimed to 
compare transition rates to full ‎psychosis among first-
degree relatives of patients with schizophrenia, with 
respect to their prodromal states for psychosis. 
In ‎addition, we compared the changes in the severity of 
prodromal symptoms between high-risk and low-risk 
groups during this period. ‎ 
 
Materials and Method 
 
Study Setting & Ethical Considerations: 
 
The original study was approved by the Institutional 
Review Board at Tehran University of ‎Medical 
Sciences, Tehran, Iran. Participants in this study 
provided informed consent for ‎participating in the 
study, including unidentified publication of the results 
and follow-up for ‎further investigations. No further 
evaluation was performed in case of disagreements. 
All ‎collected data were treated in line with the ethical 
guidelines of the medical research, and ‎anonymity of 
research participants was maintained.‎ 
 
Participants: 
 
We selected the participants from the first-degree 
relatives of patients with schizophrenia who ‎were 
hospitalized at Roozbeh Hospital, Tehran, Iran. These 
patients were diagnosed by an ‎attending psychiatrist 
and admitted to the hospital because of an exacerbation 
of their ‎illnesses. Participants had to be a first-degree 
relative of these patients; i.e., a biological ‎parent, a 
sibling, or an offspring. All family members aged 15 to 
35 years were approached and ‎as many who consented 
were included. ‎ 
Participants were excluded from the study if they had a 
past‎history‎of‎any‎axis‎І‎disorders,‎a‎ ‎history of taking 
antipsychotics/mood stabilizers for longer than 1 
months, a past history of ‎medical conditions that could 
present with psychotic features, or any 
physical/mental ‎impairments which prevented proper 
communication with the interviewer.‎ 
Participants were classified into two groups at baseline: 
High- and low-risk for psychosis. The ‎high-risk group 
consisted of family members who were diagnosed with 
prodromal syndromes ‎for psychosis using the 
Structured Interview for Prodromal Syndromes (SIPS) 
or reported a ‎history of any psychiatric illnesses except 
psychotic disorders or a self-reported need to 
seek ‎mental health services. Due to time constraints, 
we determined the score 2 instead of 3 in 
APS ‎(Attenuated Positive Syndrome) subscale as a 
cutoff for diagnosis of being prodromal for ‎psychosis. 
The participants in the low-risk group were the family 
members who did not fulfill ‎any of the above criteria. 
Psychosis transition among relatives of the patients with Schizophrenia 
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Fifty participants were recruited for each group, and 
both groups ‎were matched for age and sex. ‎ 
 
Structured Interview for Prodromal Syndromes 
(SIPS): ‎ 
 
The Structured Interview for Prodromal Syndromes 
(SIPS) was used to investigate prodromal ‎syndromes 
and measure the severity of associated symptoms. It 
was developed by Miller et al. ‎in New Haven, CT, 
USA (31) and consists of the Criteria of Prodromal 
Syndromes, Scale of ‎Prodromal Syndromes (SOPS), 
General Assessment of Functioning (GAF) (32), a 
checklist for ‎schizotypal personality disorder and the 
questionnaire of family history of mental illness. 
The ‎SIPS offers operative concept of three prodromal 
syndromes as follows: Brief Intermittent ‎Psychotic 
Symptom syndrome (BIPS), Attenuated Positive 
Symptom syndrome (APS), and ‎Genetic Risk and 
Deterioration syndrome (GRD). Participants with BIP 
should have experienced ‎one or more prodromal 
symptoms in the psychotic severity, with the 
symptom(s) having begun ‎within the past three months, 
and experienced them for several minutes per day at a 
frequency ‎of at least once per month. APS is a mild or 
attenuated positive syndrome in the form of ‎unusual 
thought content (delusional ideas, persecutory ideas, or 
grandiose ideas), perceptual ‎abnormalities, and 
disorganized speech that have appeared in the past year 
and experienced at ‎least once per week in the past 
month. In GRD participants had a significant drop in 
functioning ‎ (i.e., at least a 30% drop in the GAF scale) 
in the past year, and had a genetic risk in the form 
of ‎having a first-degree relative with any psychotic or 
schizotypal personality disorder (25, 31).‎ 
The predictive validity of SIPS criteria was examined 
in several other studies that selected ‎individuals with 
prodromal symptoms and followed them prospectively 
measuring naturalistic ‎conversion rates; these studies 
mostly used the English, Spanish, and Korean versions  
(33–35).‎ 
The severity of symptoms of SIPS criteria were 
measured by a comprehensive tool called the ‎Scale of 
Prodromal Symptoms (SOPS) developed by Miller et 
al. and McGlashan et al. (25, 31). ‎SOPS evaluates 5 
positive symptoms, 6 negative symptoms, 4 
disorganization symptoms, and 4 ‎general symptoms 
(Table 1).‎ 
 
Data Collection: 
 
The same senior resident of psychiatry who was trained 
conducted the interviews using the ‎instrument. The 
participants were interviewed by the same interviewer 
at two time points: At ‎baseline and one- year follow-
up. We asked the participants to come to the hospital 
for the in-‎person interview, but a small number of 
participants (N = 29) who were not able to travel to 
the ‎hospital, interviews were conducted via phone.‎ 
 
 
 
Statistical Analysis: 
All data from the baseline and follow-up evaluations 
were entered into the Statistical Package ‎for the Social 
Sciences (SPSS) Software Version 20 (IBM Corp. 
Released 2011. IBM SPSS ‎Statistics for Windows, 
Version 20.0. Armonk, NY: IBM Corp). In all 
analytical comparisons, a ‎two-sided P-value <0.05 was 
defined as a statistically significant level to refuse the 
underlying ‎null hypothesis.‎ 
1. Reliability 
Internal consistency was assessed by computing alpha 
coefficients for each of the SOPS ‎subscales and total 
scale‎ scores.‎ Cronbach’s‎ alpha‎ coefficients‎ were‎
estimated for both baseline ‎and follow-up evaluations.‎ 
2. Validity 
Spearman correlation test was applied to evaluate 
criterion validity of the SOPS total score in ‎relation 
with GAF scores at both baseline and follow-up time 
points. The underlying hypothesis ‎was to assess 
whether the instrument is valid enough to determine 
the changes in SOPS with ‎respect to the changes in 
GAF presumed to affect SOPS. ‎ 
3. Description 
The mean and standard deviation (SD) was used to 
describe numerical variables, whereas the ‎relative 
frequency percentage was used to describe nominal and 
categorical variables.‎ 
4. Analytical Comparisons 
Our data did not show a normal distribution; therefore, 
non-parametric analytical assessments ‎were employed. 
Mann Whitney U and chi square tests were applied to 
compare the differences ‎between high-risk and low-
risk groups.‎ 
 
Results 
 
Baseline characteristics: 
 
Among 216 participants who were invited, 100 
accepted to participate in our study. Participants were 
assigned into two groups: ‎High- (N = 50) and low-risk 
(N = 50) based on the presence of prodromal 
syndromes. Eight participants (4 from each group) 
refused ‎to participate in the follow-up investigations. 
No difference was found in demographic 
characteristics between participants who ‎completed the 
study and those who refused to participate in the 
follow-up evaluation. Basic socio-demographic and 
clinical data for ‎92 participants who completed the 
study are presented in Table 2. No significant 
difference was found between the high-risk and ‎low-
risk groups regarding any of the demographic and 
clinical characteristics. The mean age of the 
participants in the high-risk ‎group was 27.5(SD 5) as 
well as 26.7(SD 5.2) in the low-risk group. Near half of 
the participants were female in both high-risk and ‎low-
risk groups (47.8% vs 43.5%) and one-third of the 
participants were married (28.3% vs 32.6%), 
respectively. Similar proportions ‎of the participants 
(23.9%) in both groups were employed.‎ 
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Table 1: Items of the Scale of Prodromal Symptoms (SOPS) 
 
 
Table 2: Baseline Demographics of the Groups with High and Low Risk for ‎Psychosis 
 
 No. (%)   
 Prodrome Prodrome   
 Positive Negative   
Characteristics (N=46) (N=46)   
Age, mean(SD), yrs 27.52(4.99) 26.69(5.24)   
Female sex 22(47.8) 20(43.5) 0.17(1) 0.67 
Relationship with patient     
Sibling 40(87) 44(95.6) 1.16(2) 0.56 
offspring 6(13) 2(4.4)   
Current marital status     
Married 13(28.3) 15(32.6) 1.15(2) 0.56 
Single/Divorced 33(71.7) 31(67.4)   
Current work situation     
Fulltime 11(23.9) 11(23.9) 10.10(6) 0.12 
Part-time 3(6.5) 12(26.1)   
Homemaker 13(28.3) 12(26.1)   
Student 6(13) 6(13)   
Retired 3(6.5) 0(0)   
Unemployed 6(13) 3(6.5)   
Other 4(8.7) 2(4.3)   
Education     
Illiterate 0(0) 2(4.4) 8.9(5) 0.11 
Primary 5(10.9) 0(0)   
Elementary 17(37) 12(26.7)   
Diploma 10(21.7) 14(31.1)   
BS degree 5(10.9) 7(15.6)   
MS and higher 9(19.6) 10(22.2)   
Family history of psychiatric     
Disorder (other than the proband)     
None     
First degree 29(65.9) 28(63.7)   
Second degree 7(15.9) 10(22.7)   
Family history of psychiatric 8(18.2) 6(13.6) 0.83(3) 0.84 
Symptom Classification Items 
Positive Symptoms 
P1. Unusual thought content/Delusional ideas 
P2. Suspiciousness/Persecutory ideas 
P3. Grandiosity 
P4. Perceptual abnormalities/Hallucinations 
P5. Disorganized communication 
Negative symptoms 
N1. Social anhedonia or withdrawal 
N2. Avolition 
N3. Decreased expression of emotion 
N4. Decreased experience of emotions and self 
N5. Decreased ideational richness 
N6. Deterioration in role functioning 
 
Disorganization symptoms 
D1. Odd behavior or appearance 
D2. Bizarre thinking 
D3. Trouble with focus and attention 
D4. Personal hygiene/Social attentiveness 
General symptoms 
G1. Sleep disturbance 
G2. Dysphoric mood 
G3. Motor disturbances 
G4. Impaired tolerance to normal stress 
Psychosis transition among relatives of the patients with Schizophrenia 
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Table 3: Comparison of the Baseline Severity of Prodromal Symptoms between ‎the Groups with High- and Low-
Risk for Psychosis ‎ 
 
 
Tablel 4: Comparison of the Follow-up Severity of Prodromal Symptoms‎ between the Groups with High- and 
Low-Risk for Psychosis 
Clinical Variables High risk (N=46) Low risk (N=46) 
Man Whitney 
P value 
 SIPS positive symptoms, mean (SD) 
Unusual thought content 
Suspiciousness 
Grandiose ideas 
Perceptual abnormalities 
Disorganized communication 
 
3.03(1.64) 
2.36(1.85) 
0.71(1.33) 
1.54(1.77) 
0.29(0.66) 
 
0.5 (0.64) 
0.42(0.64) 
0.12(0.33) 
0.48(1.5) 
0.02(0.16) 
 
< 0.001* 
< 0.001* 
0.05 
< 0.001* 
0.03 
SIPS negative symptoms, mean (SD) 
Social anhedonia or withdrawal 
Avolition 
Decreased expression of emotion 
Decreased experience of self 
Decreased ideational richness 
Deterioration in role functioning 
 
1(1.36) 
1.29(1.61) 
0.50(0.88) 
0.50(1.04) 
0.32(0.77) 
1.57(1.71) 
 
0.12(0.40) 
0.22(0.58) 
0.05(0.22) 
0.12(0.40) 
0.0 (0.0) 
0.40(0.74) 
 
< 0.001* 
< 0.001* 
0.04 
0.07 
0.02* 
< 0.001* 
SIPS disorganized symptom, mean(SD) 
Odd behavior or appearance 
Bizarre thinking 
Trouble with focus and attention 
Personal hygiene/ social attentiveness 
 
0.11 (0.42) 
0.36 (0.83) 
1.82(1.89) 
0.54(1.10) 
 
0.0 (0.0) 
0.0 (0.0) 
0.65(1) 
0.10(0.39) 
 
0.12 
< 0.001* 
< 0.001* 
0.04 
SIPS general symptoms, mean (SD) 
Sleep disturbance 
Dysphoric mood 
Motor disturbance 
Impaired tolerance to normal stress 
 
1.71(1.70) 
2.93(1.78) 
0.0 (0.0) 
2.21(1.77) 
 
0.47(0.93) 
1.10(1.08) 
0.0 (0.0) 
0.72(0.96) 
 
< 0.001* 
< 0.001* 
0.47 
< 0.001* 
Clinical Variables High risk (N=46) Low risk (N=46) 
Man Whitney 
P value 
SIPS positive symptoms, mean (SD) 
Unusual thought content 
Suspiciousness 
Grandiose ideas 
Perceptual abnormalities 
Disorganized communication 
 
2.43 (1.1) 
1.82 (1.33) 
0.61 (1.06) 
1.07 (1.25) 
0.29 (0.66) 
 
0.45 (0.55) 
0.35 (0.53) 
0.12 (0.33) 
0.25 (0.49) 
0.02 (0.16) 
 
< 0.001* 
< 0.001* 
0.05 
< 0.001* 
0.03 
SIPS negative symptoms, mean (SD) 
Social anhedonia or withdrawal 
Avolition 
Decreased expression of emotion 
Decreased experience of self 
Decreased ideational richness 
Deterioration in role functioning 
 
0.75 (0.27) 
0.71 (0.90) 
0.32 (0.67) 
0.46 (1.04) 
0.25 (0.59) 
1 (1.12) 
 
0.07 (0.27) 
0.15 (0.43) 
0.0(0.0) 
0.02 (0.16) 
0.0(0.0) 
0.37 (0.70) 
 
< 0.001* 
< 0.001* 
0.01* 
< 0.001* 
0.02* 
0.02* 
SIPS disorganized symptom, mean(SD) 
Odd behavior or appearance 
Bizarre thinking 
Trouble with focus and attention 
Personal hygiene/ social attentiveness 
 
0.11 (0.42) 
0.36 (0.83) 
1.21 (1.2) 
0.25 (0.52) 
 
0.0 (0.0) 
0.02 (0.16) 
0.60 (0.87) 
0.02 (0.16) 
 
0.12 
0.01* 
0.01* 
0.01* 
SIPS general symptoms, mean (SD) 
Sleep disturbance 
Dysphoric mood 
Motor disturbance 
Impaired tolerance to normal stress 
 
1.25 (1.29) 
2.04 (1.32) 
0.0 (0.0) 
1.40 (1.10) 
 
0.47 (0.82) 
1.25 (1.06) 
0.0 (0.0) 
0.62 (0.84) 
 
0.01 
< 0.001* 
0.48 
< 0.001* 
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Graph 1: Flowchart of inclusion and follow-up‎of‎patient’s 
 
 
 
Reliability: 
 
At baseline, the Cronbach’s‎ alpha‎ coefficient‎ for‎ the‎
SOPS total score was 0.89, with an alpha value of 0.69 
for the positive ‎symptoms subscale, 0.81 for the 
negative symptoms subscale, 0.45 for the 
disorganization symptoms, and 0.69 for the 
general ‎symptoms subscale. Besides, at follow-up, the 
Cronbach’s‎ alpha‎ coefficient‎ for‎ the‎SOPS‎ total‎ score‎
was 0.929, with an alpha level of ‎0.78, 0.78, 0.5 and 
0.8 for the positive, negative, disorganization and 
general symptoms subscales, respectively.‎ 
 
Validity: 
 
In order to assess the criterion validity of the SOPS 
scale, the total scores of SOPS were correlated with 
GAF scores. At baseline ‎evaluations, there was a 
significant indirect correlation between the SOPS total 
score and GAF scores with correlation coefficient of -
‎0.7(P <0.001). Likewise at follow-up, there was a more 
significant and indirect correlation between the SOPS 
total score and GAF ‎score with correlation coefficient 
of -0.87(P <0.001).‎ 
High-risk group demonstrated significantly higher 
severity in all SIPS items at‎ baseline,‎ except‎ in‎ “odd‎
behavior‎ or‎ appearance”‎ and‎ ‎“motor‎ disturbance”‎ in‎
which the differences were not statistically significant 
with P values of 0.12 and 0.48, respectively (Table 3).  
After the 12-month follow-up, the high-risk group 
continued to illustrate higher severity in almost all 
SIPS items, which were ‎statistically significant. 
Interestingly,‎ the‎ difference‎ in‎ “odd‎ behavior‎ or‎
appearance”‎ and‎ “motor‎ disturbance”‎ remained‎
statistically ‎insignificant with p values of 0.12 and 
0.47, respectively Table 4. Furthermore, the difference 
between the two groups appeared ‎statistically 
insignificant‎ (P‎ =‎ 0.07)‎ in‎ “decreased‎ experience‎ of‎
self”‎ item‎ at‎ follow-up. As illustrated in Graph 1, six 
participants in ‎the high-risk group developed a full 
psychosis after a 12- month follow-up, which resulted 
in conversion rate of 13% (95% CI [0.029, ‎0.23]) and 
other participants remained high-risk through the 
follow-up period. Besides, three participants in the 
low-risk group ‎became high-risk -prodromal for 
psychosis- at follow-ups. None of the participants in 
the low-risk group converted to a full psychosis ‎in this 
period.‎ 
 
Discussion 
 
 
We found higher transition rate to full psychosis 
among the high-risk group compared to low-risk within 
one-year follow-up as we ‎demonstrated 13% transition 
rate to full psychosis in the high-risk group and zero in 
the low-risk participants. The high-risk group ‎had a 
significantly more severe positive, negative, 
disorganization, and general symptoms at baseline and 
continued to have more ‎severe symptoms at one-year 
follow-up. ‎ 
Previous studies have revealed a wide range of 
transition rates to full psychosis among people with 
prodromal syndrome during ‎different follow-up 
periods. For example, a study with 9.6 years follow-up 
reported 70% conversion rate (28). While Cannon 
and ‎colleagues reported conversion rates in 6, 12, 18, 
24 and 30 months follow-ups point by point ( 12.7, 
21.7, 26.8, 32.6, 35.3%), ‎respectively (30). In another 
study, conversion rate after the one- year follow-up 
were reported at 22%. [18] At first glance, it seems ‎that 
literature has reported higher rates of transition to full 
psychosis compared to our study. However, such a 
difference is probably ‎due to larger sample sizes, 
longer duration of follow-up or inclusion of persons 
with more severe symptoms. ‎ 
Furthermore, there is evidence for the application of 
prodromal syndromes for other mental disorders. In a 
recent study, attenuated ‎positive symptoms based on 
Psychosis transition among relatives of the patients with Schizophrenia 
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the SIPS has been shown to be associated with greater 
suicidality and psychopathology severity in a ‎sample of 
13 to 35 year-old participants seeking mental help (37). 
Besides, considering the results of a 5-year prospective 
study of ‎adolescents with severe behavioral problems, 
the SIPS demonstrated limited power for anticipating 
psychosis, whereas it appeared ‎to be useful for mood 
and conduct disorders (38). These findings could 
propose the implementation of the SIPS not only as 
a ‎psychosis risk-screening tool, but also as a measure, 
assessing more global aspects of mental health.‎ 
A study conducted by Schlosser's et al. with 40 high-
risk participants and one-year follow-up duration is 
similar to ours. They also ‎reported 12.5% transition 
rate to full psychosis, which is similar to our results. 
(36). Taken together, all of these 
investigations ‎reported a transition rates to psychosis 
between 6.6% (26) and 54% (27) with mean follow-up 
durations ranging between 6 to 12 ‎months [9]. We 
included patients with less severe prodromal symptoms 
in the high-risk group with relatively shorter duration 
of ‎follow-up; therefore, relatively low conversion rate 
to psychosis could be the result of our recruitment 
criteria. ‎ 
In contrast to our results, Schlosser showed that the 
severity of symptoms decreased‎in‎36%‎of‎the‎”clinical‎
high‎ risk”‎ participants‎ ‎during two-and-a-half year 
follow-up; and consequently, 30% of them experienced 
functional improvements. However, we ‎concluded that 
no one experienced a decline in severity of the 
symptoms or improvement in the total functional state. 
This could be ‎explained by larger sample size and 
longer duration of follow-up of Schlosser's study (30). 
In addition, we included persons with ‎minimum of 2 
instead of 3 on the basis of attenuated psychotic 
syndrome which can explain higher proportion of the 
high-risk group ‎after a one- year follow-up in our 
study. ‎ 
 
Limitations 
 
This study had weaknesses that should raise caution in 
any interpretation of the findings: First, small sample 
size led to limitation in ‎detection of statistically 
significant differences and low conversion rates. 
Second was the short duration of the follow-up which 
may ‎have resulted in less precise transition rate to full 
psychosis. Third, validity of some SIPS items for 
Persian speaking patients is in ‎question; e.g., some 
items‎ that‎ assess‎ “unusual‎ thought‎ content”‎ and‎
“perceptual‎ abnormalities”‎ were‎ vague‎ and‎
hardly ‎understandable for some participants. Further 
validation studies of the Persian translation are 
warranted. Fourth, we did not use a ‎comprehensive 
assessment tool to confirm diagnosis at the end of the 
follow-up period. The assessments would have been 
improved ‎if we had confirmed our diagnosis after the 
one-year follow-up with structured instruments such as 
the Structured Clinical Interview ‎for DSM-IV (SCID). 
However, we were more interested in detecting 
transition to any psychotic illness rather than any 
particular ‎disorder. Nevertheless, this study has some 
strengths including low rate of loss to follow-up, 
having a control group, being the first ‎study using the 
Persian translation of the SIPS and measuring 
transition to full psychosis rate of at-risk subjects 
among relatives of ‎patients with schizophrenia.‎ 
 
Conclusion 
 
This study confirmed the predictive validity of 
prodromal syndromes for future psychosis in high-risk 
participants. In a group of first-‎degree relatives of 
patients with schizophrenia, the presence of prodromal 
syndromes not only raises the risk of conversion 
to ‎psychosis, but also prodromal psychotic symptoms 
appeared to be persistent at least for one year.‎ 
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